In 2002, the US Food and Drug Administration (FDA) approved mesh for the surgical treatment of pelvic organ prolapse and in 2008 released a public health notification of risks associated with this use of surgical mesh.1 In 2011, the FDA released an updated communication questioning the effectiveness of vaginally placed mesh as compared with the nonmesh repair of pelvic organ prolapse and reported 1503 mesh-related events (5-fold increase) in the Manufacturer and User Device Experience database from January 1, 2008, through December 31, 2010.2 We sought to determine the extent of use of vaginal mesh in pelvic organ prolapse after the most recent FDA warning and patterns of discontinuation of the use of vaginal mesh in New York State.
Sedrakyan A, Chughtai B, Mao J. Regulatory Warnings and Use of Surgical Mesh in Pelvic Organ Prolapse. JAMA Intern Med. 2016;176(2):275-277. doi:10.1001/jamainternmed.2015.6595